AtaiBeckley (ATAI) EPS (Weighted Average and Diluted) (2021 - 2026)
AtaiBeckley recorded quarterly EPS (Weighted Average and Diluted) of -$0.28 in Q3 2025, down 100.0% quarter-over-quarter from -$0.14 in Q2 2025, and down 75.0% year-over-year from -$1.12 in Q3 2024.
AtaiBeckley has reported EPS (Weighted Average and Diluted) for 2 years, with the latest figure at -$0.08 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 46.67% year-over-year to -$0.08; the trailing twelve-month figure through Mar 2026 stood at -$0.16 (changed N/A YoY), and the FY2025 full-year result was -$2.91, down 212.9% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.28 for Q3 2025 at AtaiBeckley, down from -$0.14 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.08 in Q1 2026, with the low at -$0.15 in Q1 2025.
- A 5-year average of -$0.21 and a median of -$0.21 in 2021 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) slumped 2500.0% in 2022 and jumped 213.64% in 2023, its largest moves.
- AtaiBeckley's EPS (Weighted Average and Diluted) stood at -$0.62 in 2021, then surged by 53.23% to -$0.29 in 2022, then jumped by 62.07% to -$0.11 in 2023, then sank by 118.18% to -$0.24 in 2024, then decreased by 16.67% to -$0.28 in 2025.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.28, -$0.14, and -$0.15 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | AtaiBeckley | 1.62 Bn | 1.62 Bn | - | -0.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.08 |
| Sep 30, 2025 | -0.28 |
| Jun 30, 2025 | -0.14 |
| Mar 31, 2025 | -0.15 |
| Mar 31, 2025 | -0.15 |
| Dec 31, 2024 | -0.24 |
| Sep 30, 2024 | -0.16 |
| Jun 30, 2024 | -0.36 |
| Mar 31, 2024 | -0.17 |
| Dec 31, 2023 | -0.11 |
| Sep 30, 2023 | 0.25 |
| Jun 30, 2023 | -0.21 |
| Mar 31, 2023 | -0.21 |
| Dec 31, 2022 | -0.29 |
| Sep 30, 2022 | -0.22 |
| Jun 30, 2022 | -0.24 |
| Mar 31, 2022 | -0.24 |
| Dec 31, 2021 | -0.62 |
| Sep 30, 2021 | -0.21 |
| Jun 30, 2021 | -0.37 |
| Mar 31, 2021 | 0.01 |